Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 14
2006 40
2007 77
2008 96
2009 151
2010 163
2011 223
2012 230
2013 217
2014 207
2015 190
2016 212
2017 211
2018 223
2019 203
2020 217
2021 222
2022 190
2023 172
2024 84

Text availability

Article attribute

Article type

Publication date

Search Results

2,919 results

Results by year

Filters applied: . Clear all
Page 1
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.
Kantarjian HM, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Boquimpani C, Pasquini R, Clark RE, Dubruille V, Flinn IW, Kyrcz-Krzemien S, Medras E, Zanichelli M, Bendit I, Cacciatore S, Titorenko K, Aimone P, Saglio G, Hochhaus A. Kantarjian HM, et al. Leukemia. 2021 Feb;35(2):440-453. doi: 10.1038/s41375-020-01111-2. Epub 2021 Jan 7. Leukemia. 2021. PMID: 33414482 Free PMC article. Clinical Trial.
Estimated 10-year overall survival rates in nilotinib and imatinib arms were 87.6%, 90.3%, and 88.3%, respectively. Overall frequency of adverse events was similar with nilotinib and imatinib. By 10 years, higher cumulative rates of cardiovascular events were report …
Estimated 10-year overall survival rates in nilotinib and imatinib arms were 87.6%, 90.3%, and 88.3%, respectively. Overall frequency …
Nilotinib modulates LPS-induced cognitive impairment and neuroinflammatory responses by regulating P38/STAT3 signaling.
Kim J, Lee HJ, Park JH, Cha BY, Hoe HS. Kim J, et al. J Neuroinflammation. 2022 Jul 15;19(1):187. doi: 10.1186/s12974-022-02549-0. J Neuroinflammation. 2022. PMID: 35841100 Free PMC article.
Importantly, nilotinib treatment rescued LPS-mediated spatial working memory impairment and cortical dendritic spine number in wild-type mice. CONCLUSIONS: Our results indicate that nilotinib can modulate neuroinflammatory responses and cognitive function in LPS-sti …
Importantly, nilotinib treatment rescued LPS-mediated spatial working memory impairment and cortical dendritic spine number in wild-t …
Nilotinib.
Gresse M, Kim TD, le Coutre P. Gresse M, et al. Recent Results Cancer Res. 2018;212:69-85. doi: 10.1007/978-3-319-91439-8_3. Recent Results Cancer Res. 2018. PMID: 30069625
Showing higher response rates while not leading to more adverse events, nilotinib has become an attractive option in the first-line treatment of chronic-phase chronic myeloid leukemia. By reaching deep and long-lasting molecular remissions, discontinuation of TKIs is becom …
Showing higher response rates while not leading to more adverse events, nilotinib has become an attractive option in the first-line t …
Nilotinib.
Ostendorf BN, le Coutre P, Kim TD, Quintás-Cardama A. Ostendorf BN, et al. Recent Results Cancer Res. 2014;201:67-80. doi: 10.1007/978-3-642-54490-3_3. Recent Results Cancer Res. 2014. PMID: 24756785 Review.
Subsequent advances have led to the development of novel tyrosine kinase inhibitors (TKIs). One such inhibitor, nilotinib, was rationally designed to increase its affinity and specificity for the oncogenic tyrosine kinase Bcr-Abl compared with imatinib and has been shown t …
Subsequent advances have led to the development of novel tyrosine kinase inhibitors (TKIs). One such inhibitor, nilotinib, was ration …
Nilotinib-induced lichen planopilaris.
Lahouel I, Ben Salah N, Rouatbi J, Boukhriss S, Abdejlil N, Youssef M, Belhadjali H, Laatiri A, Zili J. Lahouel I, et al. Int J Dermatol. 2022 Jan;61(1):e37-e38. doi: 10.1111/ijd.15647. Epub 2021 May 3. Int J Dermatol. 2022. PMID: 33937983 No abstract available.
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.
Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre PD, Etienne G, Dorlhiac-Llacer PE, Clark RE, Flinn IW, Nakamae H, Donohue B, Deng W, Dalal D, Menssen HD, Kantarjian HM. Hochhaus A, et al. Leukemia. 2016 May;30(5):1044-54. doi: 10.1038/leu.2016.5. Epub 2016 Feb 3. Leukemia. 2016. PMID: 26837842 Free PMC article. Clinical Trial.
Numerically more cardiovascular events (CVEs) occurred in patients receiving nilotinib vs imatinib, and elevations in blood cholesterol and glucose levels were also more frequent with nilotinib. ...These long-term results support the positive benefit-risk profile of …
Numerically more cardiovascular events (CVEs) occurred in patients receiving nilotinib vs imatinib, and elevations in blood cholester …
Nilotinib.
Quintás-Cardama A, Kim TD, Cataldo V, le Coutre P. Quintás-Cardama A, et al. Recent Results Cancer Res. 2010;184:103-17. doi: 10.1007/978-3-642-01222-8_8. Recent Results Cancer Res. 2010. PMID: 20072834 Review.
Considerable efficacy after imatinib failure has been demonstrated in clinical trials leading to nilotinib's current approval as second-line therapy for CML in chronic and accelerated phase (AP). The role of nilotinib as first-line treatment for CML, in combinatoria …
Considerable efficacy after imatinib failure has been demonstrated in clinical trials leading to nilotinib's current approval as seco …
Experience with dasatinib and nilotinib use in pregnancy.
Barkoulas T, Hall PD. Barkoulas T, et al. J Oncol Pharm Pract. 2018 Mar;24(2):121-128. doi: 10.1177/1078155217692399. Epub 2017 Feb 17. J Oncol Pharm Pract. 2018. PMID: 29284357 Review.
Animal studies with dasatinib or nilotinib demonstrate fetal skeletal malformations as well as significant mortality during organogenesis. The goal of this article is to review the experience to date of dasatinib and nilotinib in human pregnancy, specifically dasati …
Animal studies with dasatinib or nilotinib demonstrate fetal skeletal malformations as well as significant mortality during organogen …
Nilotinib.
Plosker GL, Robinson DM. Plosker GL, et al. Drugs. 2008;68(4):449-59; discussion 460-1. doi: 10.2165/00003495-200868040-00005. Drugs. 2008. PMID: 18318563 Review.
Major cytogenetic response rates did not differ between imatinib-resistant and -intolerant patients, and nilotinib was effective in patients with BCR-ABL mutations (except T315I). ...Data from the phase II trial in patients with CML in blast crisis (n = 135) also showed pr …
Major cytogenetic response rates did not differ between imatinib-resistant and -intolerant patients, and nilotinib was effective in p …
Nilotinib-associated acute pancreatitis.
Engel T, Justo D, Amitai M, Volchek Y, Mayan H. Engel T, et al. Ann Pharmacother. 2013 Jan;47(1):e3. doi: 10.1345/aph.1R334. Epub 2013 Jan 8. Ann Pharmacother. 2013. PMID: 23300151
There are few case reports of acute pancreatitis associated with nilotinib in the literature and some are incomplete. We present a well-documented case of nilotinib-associated acute pancreatitis. ...CONCLUSIONS: This case demonstrates a possible association between …
There are few case reports of acute pancreatitis associated with nilotinib in the literature and some are incomplete. We present a we …
2,919 results